RETeval-DR is built for assessing vision-threatening diabetic retinopathy (VTDR)
Sold exclusively by Welch-Allyn to an international audience.
The Welch Allyn RETeval-DR Electroretinograph is designed for healthcare providers who want to improve management of their patients with diabetes. In just three minutes, you can objectively screen for vision-threatening diabetic retinopathy (VTDR) wherever patients receive care. Welch Allyn RETeval-DR Electroretinograph enables efficient, comfortable, non-mydriatic screening for VTDR that improves patient compliance to help preserve vision in your patients with diabetes.
LKC manufactures this device for Welch Allyn, which it markets under the Welch Allyn brand name outside of the United States. Further information is available at www.RETeval-DR.com.